How Oxybutynin Can Transform Your Urinary Health？

In the pharmacological management of Overactive Bladder (OAB) and detrusor instability, Oxybutynin Hydrochloride remains the clinical benchmark. However, for pharmaceutical formulators and R&D directors, the raw API presents distinct pharmacokinetic hurdles. Standard immediate-release (IR) oral delivery triggers aggressive first-pass hepatic metabolism via the CYP3A4 enzyme. This converts the parent drug into high concentrations of N-desethyloxybutynin (N-DEO)-the primary metabolite responsible for severe anticholinergic side effects like dry mouth. At Xi'an Tihealth, we engineer our high-purity Oxybutynin API specifically to meet the stringent physical demands of next-generation transdermal patches and osmotic extended-release (ER) systems, bypassing these metabolic bottlenecks.

Unlike single-target muscarinic antagonists, Oxybutynin exerts a unique dual-inhibition dynamic on the detrusor muscle:

1. Competitive Muscarinic Blockade: It exhibits a high affinity for M1, M2, and particularly M3 muscarinic receptors on the bladder smooth muscle. By competitively blocking acetylcholine at these sites, it suppresses involuntary neurogenic contractions.

2. Direct Musculotropic Relaxation: Independent of the neurological receptor pathway, the API demonstrates a direct spasmolytic effect on the smooth muscle tissue itself. This is achieved by modulating voltage-dependent calcium channels (VDCCs), thereby increasing baseline bladder capacity and delaying the initial desire to void.

For B2B procurement, controlling residual solvents and maintaining polymorphic stability is non-negotiable for bioequivalence (BE) testing. Below are the standard specifications for our EP/USP compliant Oxybutynin Hydrochloride.

Technical Parameter	Specification Standard (USP/EP)	Analytical Method
CAS Number	1508-65-2 (Hydrochloride)	-
Assay (Titration)	≥ 99.0% - 101.0%	Dried Basis
Appearance	White to off-white crystalline powder	Visual
Melting Range	124°C – 129°C	Capillary Method
Loss on Drying (LOD)	≤ 0.5%	Gravimetric (105°C)
Related Substances	Total Impurities ≤ 1.0%	High-Resolution HPLC

The transition from oral immediate-release to Transdermal Delivery Systems (TDS) and topical gels is the current industry standard to bypass hepatic metabolism. However, this introduces a severe physical challenge: API solubility within the adhesive polymer matrix.

Large or irregular crystal habits will precipitate out of the transdermal matrix, causing erratic skin flux rates. At Xi'an Tihealth, we utilize specialized fluid-energy milling to achieve a strictly controlled micronization profile (D90). This guarantees uniform dispersion within lipophilic gel bases, ensuring steady-state serum concentrations and eliminating the high peak-to-trough fluctuations that cause adverse systemic events.

In B2B API procurement, eliminating regulatory friction is as important as the chemical purity itself. Operating under an ISO9001:2015 framework, Xi'an Tihealth provides uncompromising batch-to-batch consistency. Every lot is supported by full HPLC chromatograms, Organic Volatile Impurities (OVI) clearance reports, and technical dossiers ready to support DMF/CEP submissions in North American and European markets. View Detailed Product Specifications Here.

1. Yarker, Y. E., et al. (1995). Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs & Aging. PubMed Analysis

2. MacDiarmid, S. A. (2001). Maximizing the efficacy and tolerability of oxybutynin. Reviews in Urology. PMC Resources

3. Chancellor, M. B., et al. (2012). Transdermal oxybutynin in the management of overactive bladder. ScienceDirect Clinical Protocols

Is your Oxybutynin Hydrochloride optimized for transdermal patch formulations?

Yes. We can provide specific micronized grades with customized particle size distributions (D90) to ensure uniform dispersion and stable percutaneous flux within your specific adhesive matrix.

How do you protect the crystalline structure during international transit?

To prevent moisture ingress and polymorphic conversion, the API is vacuum-sealed inside double-layered, pharmaceutical-grade anti-static PE bags, encased in high-durability fiber drums.

Do you provide DMF-ready documentation?

Absolutely. Every shipment includes a validated COA, HPLC testing profiles, and comprehensive safety data sheets to facilitate immediate regulatory compliance and formulation testing.